Dr. Marty Makary, who led the FDA as commissioner, sat down with Men's Health for an extended interview covering peptides, testosterone replacement, vaccines, psychedelics, and other polarizing health topics. Five days after that conversation, he resigned from the role.
Makary's tenure sparked debate across medicine and public health. His willingness to discuss emerging therapies like peptides and psychedelics, alongside traditional FDA concerns about vaccines and drug safety, positioned him as a bridge between mainstream medicine and practitioners exploring newer treatment approaches. The interview touched on areas where scientific consensus remains unsettled and where patient interest often outpaces regulatory clarity.
The exit timing raised questions about what led to his departure. Makary had become a visible figure in discussions about FDA modernization, particularly around how the agency evaluates novel therapies and emerging wellness compounds. His openness to conversations about testosterone replacement therapy and peptide use reflected shifting attitudes in medicine toward treatments that fall outside conventional pharmaceutical channels.
Makary's approach represented a different regulatory philosophy than some predecessors. Rather than shutting down conversations about investigational compounds, he engaged with the science and the practitioners using these tools. This stance aligned with growing momentum in functional medicine and regenerative health circles, though it created tension with those favoring stricter enforcement of traditional drug approval pathways.
The resignation marked the end of a complicated tenure. Whether his departure reflected internal FDA pressures, political dynamics, or other factors remained unclear immediately after the announcement. What remained evident: the FDA faces real questions about how it regulates peptides, psychedelics, and other compounds sitting in gray areas between wellness and medicine. Those conversations Makary started did not end with his departure. Practitioners, patients, and policymakers continue debating how regulatory agencies should evaluate treatments that lack large randomized trials but show patient interest and preliminary evidence.